AXL and central nervous system cancer: In conclusion, our data indicate that targeting Axl for inhibition by a specific SMI such as BGB324 has robust anti-tumour effects on GBM cells and could potentially be effective in restraining tumour invasion in vivo and, in combination with other agents, could effectively prolong glioma patient survival.